PMID- 10339988
OWN - NLM
STAT- MEDLINE
DCOM- 19990604
LR  - 20190921
IS  - 0048-0444 (Print)
IS  - 0048-0444 (Linking)
VI  - 66
IP  - 2
DP  - 1999 Apr
TI  - Chromosome 8 copy numbers and the c-myc gene amplification in non-small cell lung 
      cancer. Analysis by interphase cytogenetics.
PG  - 107-12
AB  - Amplification of the c-myc gene has been reported in non-small cell lung cancer 
      (NSCLC). We performed dual color fluorescence in situ hybridization (FISH) to 
      detect amplifications of the c-myc gene on chromosome 8 to evaluate the 
      relationship between these possible abnormalities and pathological stage. Tumor 
      tissue samples were obtained from 29 patients of NSCLC in Stage I (n = 15) and 
      III (n = 14) who underwent lobectomy at Saitama Cancer Center. Samples were 
      analyzed for chromosome 8 centromere and c-myc gene by dual color FISH. The 
      numerical aberration rate of chromosome 8 was 36.8 +/- 20.3% in Stage I and 40.6 
      +/- 24.8% in Stage III. The amplification rate of c-myc gene was 48.3 +/- 15.2% 
      in Stage I and 57.4 +/- 17.0% in Stage III. There was a significnat difference in 
      the numerical aberration rate of chromosome 8 between patients who survived for 5 
      years or more (28.8 +/- 17.5%) and those who survived less than 5 years (44.7 +/- 
      23.1%). The amplification rate of c-myc gene was not different between patients 
      who survived more and less than 5 years survival, and who survived more and less 
      than 3 years. The 5 year-survival rate in patients who showed 40% or more of 
      chromosome 8 aberrations (n = 13) was 15.4%, which revealed significantly less 
      than that of patients who showed less than 40% of aberrations (n = 16) (56.3%). 
      There was no difference between the 5 year-survival rate in patients whose 
      amplification rates of c-myc gene were equal or more than 50% (n = 16) and less 
      than 50% (n = 13) (25.0% and 53.9%). The rate of chromosome 8 aberrations and the 
      c-myc gene amplification rate were not correlated with pathological stage. 
      However, the rate of chromosome 8 aberration showed correlation in terms of 
      longevity of survival rate, therefore we considered the rate of chromosome 8 
      aberration to be an additional prognostic factor of patient with NSCLC.
FAU - Kubokura, H
AU  - Kubokura H
AD  - Department of Surgery Second, Nippon Medical School, Tokyo, Japan.
FAU - Koizumi, K
AU  - Koizumi K
FAU - Yamamoto, M
AU  - Yamamoto M
FAU - Tanaka, S
AU  - Tanaka S
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Nihon Ika Daigaku Zasshi
JT  - Nihon Ika Daigaku zasshi
JID - 7505726
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Non-Small-Cell Lung/*genetics/mortality
MH  - Chromosome Aberrations
MH  - *Chromosomes, Human, Pair 8
MH  - Female
MH  - *Gene Amplification
MH  - *Genes, myc
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Interphase
MH  - Lung Neoplasms/*genetics/mortality
MH  - Male
MH  - Middle Aged
MH  - Prognosis
EDAT- 1999/05/26 00:00
MHDA- 1999/05/26 00:01
CRDT- 1999/05/26 00:00
PHST- 1999/05/26 00:00 [pubmed]
PHST- 1999/05/26 00:01 [medline]
PHST- 1999/05/26 00:00 [entrez]
AID - 10.1272/jnms.66.107 [doi]
PST - ppublish
SO  - Nihon Ika Daigaku Zasshi. 1999 Apr;66(2):107-12. doi: 10.1272/jnms.66.107.